{"name":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","slug":"chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"TQB2102 Injection","genericName":"TQB2102 Injection","slug":"tqb2102-injection","indication":"Phase 3 for TQB2102 Injection is not publicly available.","status":"phase_3"},{"name":"TQB2930 injection","genericName":"TQB2930 injection","slug":"tqb2930-injection","indication":"Other","status":"phase_1"},{"name":"TQB2102 for injection","genericName":"TQB2102 for injection","slug":"tqb2102-for-injection","indication":"Phase 3 for TQB2102 for injection is not publicly available.","status":"phase_3"},{"name":"TQB2210 Injection","genericName":"TQB2210 Injection","slug":"tqb2210-injection","indication":"Other","status":"phase_1"},{"name":"TQB2868 injection","genericName":"TQB2868 injection","slug":"tqb2868-injection","indication":"Phase 3 for TQB2868 injection is not publicly available.","status":"phase_3"},{"name":"TQB2922 for injection","genericName":"TQB2922 for injection","slug":"tqb2922-for-injection","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Gemcitabine hydrochloride for injection","genericName":"Gemcitabine hydrochloride for injection","slug":"gemcitabine-hydrochloride-for-injection","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Docetaxel combined + Trastuzumab +Pertuzumab","genericName":"Docetaxel combined + Trastuzumab +Pertuzumab","slug":"docetaxel-combined-trastuzumab-pertuzumab","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"TQB2930+ chemotherapy","genericName":"TQB2930+ chemotherapy","slug":"tqb2930-chemotherapy","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Tislelizumab+Oxaliplatin+Capecitabine","slug":"tislelizumab-oxaliplatin-capecitabine","indication":"Gastric or gastroesophageal junction cancer (Phase 3 development)","status":"phase_3"},{"name":"Trastuzumab+ chemotherapy","genericName":"Trastuzumab+ chemotherapy","slug":"trastuzumab-chemotherapy","indication":"HER2-positive metastatic breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"TQB2102 Injection","genericName":"TQB2102 Injection","slug":"tqb2102-injection","phase":"phase_3","mechanism":"TQB2102 Injection's mechanism is not publicly available.","indications":["Phase 3 for TQB2102 Injection is not publicly available."],"catalyst":""},{"name":"Gemcitabine hydrochloride for injection","genericName":"Gemcitabine hydrochloride for injection","slug":"gemcitabine-hydrochloride-for-injection","phase":"phase_3","mechanism":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.","indications":["Pancreatic cancer","Non-small cell lung cancer","Breast cancer","Ovarian cancer","Bladder cancer"],"catalyst":""},{"name":"TQB2930 injection","genericName":"TQB2930 injection","slug":"tqb2930-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Docetaxel combined + Trastuzumab +Pertuzumab","genericName":"Docetaxel combined + Trastuzumab +Pertuzumab","slug":"docetaxel-combined-trastuzumab-pertuzumab","phase":"phase_3","mechanism":"This combination uses a microtubule-stabilizing chemotherapy agent (docetaxel) together with two HER2-targeting monoclonal antibodies (trastuzumab and pertuzumab) to inhibit HER2-driven cancer cell growth through multiple mechanisms.","indications":["HER2-positive metastatic breast cancer","HER2-positive gastric cancer (potential)"],"catalyst":""},{"name":"TQB2102 for injection","genericName":"TQB2102 for injection","slug":"tqb2102-for-injection","phase":"phase_3","mechanism":"TQB2102 for injection's mechanism is not publicly available.","indications":["Phase 3 for TQB2102 for injection is not publicly available."],"catalyst":""},{"name":"TQB2210 Injection","genericName":"TQB2210 Injection","slug":"tqb2210-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQB2868 injection","genericName":"TQB2868 injection","slug":"tqb2868-injection","phase":"phase_3","mechanism":"TQB2868 injection's mechanism is not publicly available.","indications":["Phase 3 for TQB2868 injection is not publicly available."],"catalyst":""},{"name":"TQB2922 for injection","genericName":"TQB2922 for injection","slug":"tqb2922-for-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQB2930+ chemotherapy","genericName":"TQB2930+ chemotherapy","slug":"tqb2930-chemotherapy","phase":"phase_3","mechanism":"TQB2930 is a chemotherapy drug that targets cancer cells.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Tislelizumab+Oxaliplatin+Capecitabine","slug":"tislelizumab-oxaliplatin-capecitabine","phase":"phase_3","mechanism":"This combination uses a PD-1 inhibitor to enhance immune response against cancer cells while chemotherapy agents directly kill rapidly dividing cells.","indications":["Gastric or gastroesophageal junction cancer (Phase 3 development)"],"catalyst":""},{"name":"Trastuzumab+ chemotherapy","genericName":"Trastuzumab+ chemotherapy","slug":"trastuzumab-chemotherapy","phase":"phase_3","mechanism":"Trastuzumab is a monoclonal antibody that blocks HER2 signaling on cancer cells, combined with chemotherapy to enhance tumor cell death.","indications":["HER2-positive metastatic breast cancer","HER2-positive gastric cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOcVZRRENYWF9Ld09GXzVFS1g5a0VfUHREMzhTSXp0SGVPZ3BIN2JiVjdpclFpZjdGQWh4eHZrekFzWW9FcnpwM3I0Q2VnTzUzTUNBc0hjenN1dVdOeTFtbzl3dEVYVnRqcHpTT2FyM3F3Zkg3bFNPNGVoS0tCUF9lMWY2RzR1eUhGcklRTjBGcjhBVHpfZnFhZ2NmYzRYVDhMM1U4MA?oc=5","date":"2024-03-18","type":"deal","source":"BioWorld News","summary":"Biotheus, Hansoh ink potential ¥5B deal for new bispecific ADCs - BioWorld News","headline":"Biotheus, Hansoh ink potential ¥5B deal for new bispecific ADCs","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_3":8,"phase_1":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}